Emergent BioSolutions Inc.(EBS)Stock Analysis

EBS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Emergent BioSolutions Inc. (EBS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EBS at 50.9/100 on a 32-signal composite quality model, placing it at rank #1,426 of 2,879 stocks — the top half of the AI-ranked universe. EBS scores in the top quartile across profitability (83.6), balance sheet strength (83.6). Areas of concern include revenue growth (7.6) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Emergent BioSolutions Inc. reports quarterly revenue of $156.1M, net income of $6.8M, free cash flow of $-36.2M. Top institutional holders of EBS by reported 13-F value include BlackRock,, STATE STREET, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. EBS trades on the NYSE exchange and files with the SEC under CIK 1367644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EBS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Emergent BioSolutions Inc. directly from SEC EDGAR. Emergent BioSolutions Inc.'s 13F Pro composite quality score has ranged between 8 and 77 since 2021, currently 50.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.